Biomarker Banter: HR+/HER2- mBC Insights
Released On
January 15, 2025
Expires On
January 14, 2026
Media Type
Internet
Completion Time
1h 55 minutes
Specialty
Oncology
Topics
Breast Cancer
This activity is jointly provided by Nexus Healthcare Education and Partners for Advancing Clinical Education (PACE).
This program has been funded by an unrestricted educational grant from Eli Lilly.
Credit Available
- Physicians - maximum of 1.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of community-based US healthcare providers involved in the care of patients with HR+/HER2- mBC, including:
- Oncologists
- Advanced practice providers
- Pathologists
Program Overview
Episode 1: Biomarker basics: Paving the way for personalized breast cancer care
Chair: Komal Jhaveri
Faculty: Manali Ajay Bhave and Hope Rugo
Duration: 22:07 minutes
Episode 2: Liquid biopsies in breast cancer – practical advice for healthcare providers
Chair: Komal Jhaveri
Faculty: Erika Hamilton and Aditya Bardia
Duration: 14:55 minutes
Episode 3: Biomarker masterclass: An expert guide to best practice in HR+/HER2- mBC
Chair: Komal Jhaveri
Faculty: Reshma L. Mahtani and Jane Lowe Meisel
Duration: 19:44 minutes
Episode 4: From lab report to treatment plan: Decoding biomarker test results
Chair: Komal Jhaveri
Faculty: Sunil Badve and Kevin Kalinsky
Duration: 23:41 minutes
Episode 5: Cracking the code of endocrine therapy resistance in HR+/HER2- mBC
Chair: Komal Jhaveri
Faculty: Sara Tolaney and William J. Gradishar
Learning Objectives
Upon completion of this educational activity, learners will be better able to:
- Discuss the role of biomarker testing in breast cancer diagnosis, prognosis, treatment selection, and monitoring
- Identify the role of liquid biopsies alongside traditional tissue biopsies to inform clinical practice
- Apply the latest guideline recommendations for biomarker testing in HR+/HER2- mBC
- Evaluate biomarker test results to inform therapeutic decision-making
- Describe the essential role of multidisciplinary collaboration in optimizing biomarker testing
- Recognize ET resistance mechanisms and how biomarker testing can determine optimal treatment strategies
Faculty
Aditya Bardia, MD
Professor of Medicine
Geffen School of Medicine, UCLA
Professor Bardia is an internationally renowned breast oncologist known for his pioneering clinical and translational research in the field of cancer therapeutics, particularly in antibody–drug conjugates (ADCs). He led the development of sacituzumab govitecan, the first ADC approved for patients with metastatic triple-negative breast cancer, as well as others including trastuzumab deruxtecan and datopotamab deruxtecan. He also led the clinical development of elacestrant, the first oral selective oestrogen receptor degrader approved for patients with metastatic hormone receptor-positive breast cancer.
In translational collaboration with various labs, Professor Bardia identified the role of ESR1 mutations in mediating endocrine resistance, RB1 mutations in mediating CDK 4/6i resistance and TOP1 mutations in mediating ADC resistance.
Besides cutting-edge research, Professor Bardia is highly regarded among peers as an excellent mentor and strong advocate for academic trainees and junior faculty members. He has received several awards including the outstanding Award for Research Excellence from the Mayo Clinic, the Young Investigator Award from the American Society of Clinical Oncology, the Distinguished Researcher Award from the Massachusetts Society of Clinical Oncologists and the Douglas Family Foundation prize for excellence in oncology research.
Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Dr. Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a National Collegiate Athletics Association Postgraduate Scholarship. She then completed her medical degree and residency at the University of North Carolina in Chapel Hill and fellowship training in oncology at Duke University. She joined the Sarah Cannon Research Institute as investigator in drug development for women’s cancers in 2013. Since 2015, she has served as the Director of the Breast Cancer Research Program. She sees patients facing breast cancers undergoing treatments from the standard of care to drugs in phase II/III as well as phase I and first in human.
Dr. Hamilton was Chair of the American Society of Clinical Oncology (ASCO) Scientific Committee for Metastatic Breast Cancer from 2019–2020. She served on the Board of Directors for Susan G. Komen middle Tennessee for 3 years running and is an Associate Editor for Clinical Breast Cancer. She was named on the “Women to Watch Class of 2021” list for Nashville Medical News. She was also in ASCO’s Leadership Development Class for 2021–2022.
Hope S. Rugo, MD, FASCO
Professor of Medicine (Hematology/Oncology) University of California at San Francisco (UCSF)
Professor Rugo joined the Breast Care Center after a decade of experience at UCSF in malignant haematology and bone marrow transplantation for a variety of diseases, including breast cancer. Professor Rugo is also the Director of Breast Oncology and Clinical Trials Education at the centre. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early- and late-stage breast cancer and has published widely in this area.
Professor Rugo is an investigator and Chair of the Safety Committee for the multicentre, adaptively randomised phase II I-SPY2 trial and serves on the Novel Agents Committee. She is the Co-Chair of the Triple-Negative Working Group, an active member of the Translational Breast Cancer Research Consortium (TBCRC) and is the principal investigator of several TBCRC trials. She is also an active member of the Alliance (formerly CALGB) Breast Committee, as well as the American Society of Clinical Oncology, where she serves on the Guidelines Committee and as an editor for the Education Committee.
Professor Rugo regularly lectures locally, nationally and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Professor Rugo runs the Breast Forum, an open bimonthly evening educational session for patients with breast cancer and their families and friends. She has received several awards including an honour for her work in Breast Cancer Research by the Friends of the Breast Care Center and the Cancer Care Physician of the Year Award in 2010 from the Cancer Care National Organization.
Jane Lowe Meisel, MD, FASCO
Professor of Hematology and Medical Oncology
Co-Director, Breast Medical Oncology
Winship Cancer Institute at Emory University
Professor Meisel joined the Glenn Family Breast Center at Winship Cancer Institute as a practicing physician in 2015. She now serves as the Co-Director of Breast Medical Oncology, as well as her two appointments in the Department of Hematology and Medical Oncology, and the Department of Gynecology and Obstetrics. Professor Meisel has a special interest in women's health and in cancers that affect women.
Professor Meisel is a member of the Eastern Cooperative Oncology Group (ECOG) and is an active member of ECOG’s Breast Core Committee. She has been a regular volunteer at the American Society of Clinical Oncology (ASCO) since she joined Emory’s faculty, and currently serves as the Chair-Elect of ASCO’s Cancer Communications Committee. She will serve as Chair of the Committee next year.
Professor Meisel has presented her research on breast cancer and gynaecologic malignancies at national meetings and published her work in peer-reviewed journals. Her research is focused on the development of new therapeutic options for women with breast cancers, and on improving quality of life for these patients. She serves as the principal investigator for many therapeutic trials for patients with breast cancer at the Winship Cancer Institute and has mentored many medical oncology fellows.
Kevin Kalinsky, MD, MS
Professor of Hematology and Medical Oncology Emory University School of Medicine
Professor Rugo joined the Breast Care Center after a decade of experience at UCSF in malignant haematology and bone marrow transplantation for a variety of diseases, including breast cancer. Professor Rugo is also the Director of Breast Oncology and Clinical Trials Education at the centre. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early- and late-stage breast cancer and has published widely in this area. Professor Kalinsky is Medical Oncology Division Director in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as the Director of the Glenn Family Breast Center at Winship Cancer Institute where he is tasked with fulfilling the vision to improve breast cancer outcomes by aligning research and education with cancer treatment and prevention.
Professor Kalinsky's research focuses on new drug development and therapies for patients with early-stage and metastatic breast cancer. His work involves the development of clinical trials to assess novel therapeutic agents in breast cancer based on tumour genomics. He is funded by a number of sources, including the National Institutes of Health and the Breast Cancer Research Foundation.
Professor Kalinsky is a recipient of the Ewig Clinical Scholar Teaching Award from Columbia University, the National Cancer Institute Cancer Clinical Investigator Team Leadership Award, the Physician of Impact Award from Susan G. Komen Greater NYC and the Southwest Oncology Group Career Engagement Award.
Komal Jhaveri, MD, FACP
Professor of Medicine (Hematology/Oncology) University of California at San Francisco (UCSF)
Memorial Sloan Kettering Cancer Center (MSKCC)
Dr. Jhaveri is an Associate Attending Physician and the Patricia and James Cayne Chair for Junior Faculty. She serves as the Section Head for the Endocrine Therapy Research Program within the Breast Medicine Service and is the Clinical Director for the Early Drug Development Service at MSKCC in New York. She is also an Associate Professor in the Department of Medicine at Weill Cornell Medicine.
Dr. Jhaveri’s research focuses on the development of improved therapies for patients with breast cancer by conducting novel clinical trials integrated with translational biomarker work through acquired biospecimen or imaging analyses. She has led the development of PI3K/Akt inhibitors, fibroblast growth factor receptor inhibitors, human epidermal growth factor receptor 2/ERBB2 inhibitors, oral selective oestrogen receptor degraders and antibody–drug conjugates. Her work has been published widely in many reputable journals.
Manali A. Bhave
Breast Medical Oncologist
Director of the Phase I Clinical Trials Unit
Winship Cancer Institute of Emory University
Dr. Bhave has a special interest in developing new strategies for the treatment of patients with breast cancer and is actively involved in clinical trials and early drug development. Her goal is to provide compassionate, personalised and state-of-the-art care for her patients through the use of both standard-of-care therapies and clinical trials.
Reshma L. Mahtani, DO
Chief of Breast Medical Oncology
Miami Cancer Institute, Baptist Health South Florida
Prior to her current role, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial programme across the network. She is an active clinical researcher focusing on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
Dr. Mahtani has served on the American Society of Clinical Oncology Quality Oncology Practice Initiative Steering Committee and is the Editor-in-Chief of Practice Updates (an online medical education platform for physicians). She is also on the Board of Directors for Living Beyond Breast Cancer.
Dr. Mahtani has a passion for medical education and founded an initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. She is also involved in several initiatives that enhance patients’ access to healthcare and community collaborations for education and advocacy.
Sara Tolaney, MD, MPH
Chief of the Division of Breast Oncology
Dana-Farber Cancer Institute
Dr. Tolaney is internationally recognised for her research and education leadership in breast cancer. In addition to her main role, she serves as Associate Director of the Susan F. Smith Center for Women’s Cancers, is a Senior Physician at Dana-Farber and an Associate Professor of Medicine at Harvard Medical School.
Dr. Tolaney’s research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low-risk regimen is beneficial in women with early-stage, node-negative, human epidermal growth factor receptor 2 (HER2)-positive cancers, and this work has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early-stage HER2-positive disease and has also played a significant role in the development of CDK 4/6 inhibitors, antibody–drug conjugates and immunotherapy in breast cancer.
Dr. Tolaney currently chairs several registration studies in these areas and leads many investigator-initiated trials. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals, such as the New England Journal, Lancet Oncology, Journal of Clinical Oncology and JAMA Oncology.
Sunil Badve, MD, FRCPath
Professor in the Department of Pathology and Laboratory Medicine
Vice Chair, Pathology Cancer Programs
Emory University School of Medicine
Professor Badve has made seminal contributions to the role of tumour-infiltrating lymphocytes in triple-negative breast cancer and the re-classification of thymic tumours. His team developed and patented gene signatures for thymomas and oestrogen receptor-positive breast cancer. His current work involves studying the individual biological components that culminate in the development of cancer in patients with ductal carcinoma in situ.
Professor Badve is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University. He is an active member of the Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Cancer Research Group, where he serves as the central pathologist for several breast cancer clinical trials. He also holds a professional membership with the United States and Canadian Academy of Pathologists and is a pathology member of the National Cancer Institute's Breast Cancer Steering Committee.
Professor Badve has published over 260 peer-reviewed articles and edited two books. He is Associate Editor of Clinical Breast Cancer and serves on the editorial board of several journals including JCO Precision Medicine and BMC Cancer. Professor Badve has been the recipient of the Bantz-Petronio Award for Translating Research into Practice at Indiana University. He has also received the Vladimir Totović Award from the International Academy of Pathology – German Division and has been recognised as a Komen Scholar by the Susan G. Komen Foundation multiple times.
William J. Gradishar, MD
Chief of Hematology and Oncology
Betsy Bramsen Professor of Breast Oncology
Northwestern University Feinberg School of Medicine
Professor Gradishar is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He serves as Director of the Maggie Daley Center for Women’s Cancer Care. Additionally, he is Deputy Cancer Center Director (Clinical Network) and Deputy Chief of the Division of Hematology and Medical Oncology and System Head for Medical Oncology across Northwestern Medicine. He has been Chair of the Annual Lynn Sage Breast Cancer Symposium since its inception 18 years ago. He served as Program Director of the Hematology Oncology Fellowship Training Program at Northwestern for 20 years.
Professor Gradishar is a fellow of the American College of Physicians and the American Society of Clinical Oncology (ASCO). He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group, and current Chair of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel and the NCCN Breast Cancer Prevention Panel. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the Food and Drug Administration.
Professor Gradishar has served on numerous study sections including the National Institutes of Health, the National Cancer Institute, the National Cancer Institute of France and the Czech Cancer Institute. He is a member of the editorial board for numerous journals, including the Journal of Clinical Oncology. He is the founding Editor-in Chief of the New England Journal of Medicine Journal Watch Hematology/Oncology. He is Co-Editor of The Breast, the definitive 2-volume textbook on benign and malignant breast disorders. He has published on breast cancer therapeutics, with a focus on new endocrine therapy, chemotherapy and biologic agents.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Nexus Healthcare Education (Nexus HE). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nurses Credentialing Center, to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Komal Jhaveri
Received consultancy fee from AbbVie Inc., AstraZeneca PLC, Biotheranostics, Inc., BluePrint Medicines Corporation, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Intellisphere, LLC, Jounce Therapeutics, Lilly (Eli Lilly and Company), Novartis AG, Pfizer Inc., Sanofi S.A., Scorpion Therapeutics, Inc., Seagen Inc., Sun Pharma Advanced Research Company, Synthon Biopharmaceuticals, Taiho Oncology, Inc.
Received fees for research from ADC Therapeutics, AstraZeneca PLC, BluePrint Medicines Corporation, Clovis Oncology, Inc., Context Therapeutics, LLC, Debiopharm Group, F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Immunomedics, Inc., Lilly (Eli Lilly and Company), Novartis AG, Novita Pharmaceuticals, Pfizer Inc., Puma Biotechnology, Inc., Scorpion Therapeutics, Inc., VelosBio/Merck, Zymeworks Inc.
Received travel expenses from AstraZeneca PLC, F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Intellisphere, LLC, Jounce Therapeutics, Lilly (Eli Lilly and Company), Pfizer Inc., Taiho Oncology, Inc.
Manali Ajay Bhave
Received consultancy fee for providing speaker services to Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc.
Hope Rugo
Received fees for research from AstraZeneca PLC, Daiichi Sankyo, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI Pharma, Inc., Pfizer Inc., Stemline Therapeutics, Inc.
Received consultancy fee for providing speaker services to Chugai Pharmaceutical Co., Ltd., Mylan N.V., Napo Pharmaceuticals, Inc., Puma Biotechnology, Inc., Sanofi S.A.
Erika Hamilton
Received fees for research from AbbVie Inc., Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen Inc., Aravive, ArQule, Inc., Artios, Arvinas, AstraZeneca PLC, AtlasMedx, BeiGene, Ltd., Black Diamond Therapeutics, Inc., Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cascadian Therapeutics, Inc., Clovis Oncology, Inc., Compugen Ltd., Context Therapeutics, LLC, Cullinan Oncology, Curis, Inc., CytomX Therapeutics, Inc., Daiichi Sankyo, Inc., Dana-Farber Cancer Institute, Dantari, Deciphera Pharmaceuticals, Inc., Duality Biologics, eFFECTOR Therapeutics, Inc., Eisai Co., Ltd., Ellipses Pharma, Elucida Oncology, EMD Serono, Inc., Fochon Pharmaceuticals, Fujifilm, G1 Therapeutics, Gilead Sciences, Inc., H3 Biomedicine, Harpoon Therapeutics, Hutchinson MediPharma, Immunogen, Immunomedics, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Inspirna, Inc., InventisBio Co., Ltd., Jacobio Pharmaceuticals, Karyopharm Therapeutics Inc., Kind Pharmaceuticals, Leap Therapeutics, Lilly (Eli Lilly and Company), Loxo Oncology, Lycera Corporation, Mabspace Biosciences, Macrogenics, MedImmune, Inc., Mersana Therapeutics, Merus N.V., Millennium Pharmaceuticals, Inc., Molecular Templates, Myriad Genetic Laboratories, Novartis AG, Nucana plc, Olema Pharmaceuticals, OncoMed Pharmaceuticals, Oncthryeon Therapeutics, ORIC Pharmaceuticals, Pfizer Inc., PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Inc., Plexxikon, Inc., Prelude Therapeutics Incorporated, ProfoundBio, Inc., Radius Health, Inc., Regeneron Pharmaceuticals, Inc., Relay Therapeutics, Inc., Repertoire Immune Medicines, Rgenix, Seagen Inc., Sermonix Pharmaceuticals, Inc., Shattuck Labs, Silverback Therapeutics, Inc., StemCentRx, Inc., Stemline Therapeutics, Inc., Sutro Biopharma, Inc., Syndax Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc., Taiho Oncology, Inc., TapImmune, Inc., Tesaro, Inc., Tolmar, Inc., Torque Therapeutics, Inc., Treadwell Therapeutics, Verastem Oncology, Zenith Epigenetics Ltd., Zymeworks Inc.
Received consultancy and advisory fees from Accutar Biotechnology, AstraZeneca PLC, Daiichi Sankyo, Inc., Ellipses Pharma, Entos Pharmaceuticals, Fosun Pharma, Gilead Sciences, Inc., Jazz Pharmaceuticals, Inc., Jefferies LLC, Lilly (Eli Lilly and Company), Medical Pharma Services, Mersana Therapeutics, Novartis AG, Olema Pharmaceuticals, Pfizer Inc., Roche Holding AG/Genentech, Inc., Stemline Therapeutics, Inc., Tempus Labs, Theratechnologies, Inc., Tubulis, Veracity Science, Zentalis Pharmaceuticals, Inc.
Aditya Bardia
Received fees for research (to institution) from AstraZeneca PLC, Daiichi Sankyo, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., Menarini Group, Novartis AG, Pfizer Inc., Sanofi S.A.
Received fees for consultancy and advisory board from AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Menarini, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi.
Reshma L. Mahtani
Received fees for consultancy from Agendia Inc., Amgen Inc., AstraZeneca PLC, Daiichi Sankyo, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Hologic, Inc., Lilly (Eli Lilly and Company), Novartis AG, Pfizer Inc., Sanofi S.A., Sermonix Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Puma Biotechnology, Inc.
Jane Lowe Meisel
Received consultancy fee for providing speaker services to AstraZeneca PLC, GE Healthcare, Novartis AG, Olema Pharmaceuticals, Pfizer Inc., Seagen Inc., Stemline Therapeutics, Inc.
Sunil Badve
Received fees for research from Eli Lilly and Company.
Received fees for consultancy, advisory, and speaker services from Agilent, AstraZeneca PLC, DSI Pharmaceuticals.
Kevin Kalinsky
Received fees for consultancy, advisory, and speaker services from AstraZeneca PLC, Biotheranostics, Inc., Cullinan Oncology, Cyclocel Pharmaceuticals, Inc., Eisai Co., Ltd., Eli Lilly and Company, Gilead Sciences, Inc., Immunomedics, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Prelude Therapeutics Incorporated, ProtieinQure, Puma Biotechnology, Inc., RayzeBio, Regor Therapeutics, Seattle Genetics, eFFECTOR Therapeutics, Inc.
Received fees from ADC Therapeutics as an employee.
Sara Tolaney
Received fees for consultancy and advisory board from AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc./Seagen Inc., Systimmune, Inc.
Received fees for research from Exelixis, Inc., Inc., OncoPep, Inc.
William Gradishar
Received fees for consultancy from AstraZeneca PLC, F. Hoffmann-La Roche AG/Genentech, Inc., Eli Lilly and Company, Novartis AG, Stemline Therapeutics, Inc.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Computer system hardware/software requirements
To access and participate in the mBC podcast series hosted on the Nexus HE HUB, users will need a desktop or laptop computer running Windows (version 10 or later) or macOS (version 10.14 or later). Alternatively, mobile devices such as iOS devices (iOS 14 or later) or Android devices (Android 8.0 or later) can be used. A stable broadband internet connection with a minimum download speed of 5 Mbps is required for streaming audio content. Participants should use a web browser such as Google Chrome (latest version, recommended), Microsoft Edge (latest version), Safari (latest version), or Mozilla Firefox (latest version) to access the platform. For audio playback, built-in or external speakers or headphones are necessary.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indication(s). The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and further their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions, contact [email protected].